If you have been reading about Hepatocyte growth factor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
| Property | Value | Notes |
|---|---|---|
| Primary reported target | Hepatocyte growth factor/c-Met signaling | Findings mainly from cell and animal studies. |
| Related endogenous peptide | Angiotensin IV | Dihexa is described as a stabilized analog. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for purity assessment. |
| Identity confirmation | Mass spectrometry | Provides a molecular mass check. |
| Regulatory status | Not approved for human use | Sold as a research chemical in many jurisdictions. |
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
. Note that the above relationship implies that one need only study the equation for two of the three variables. Secondly, we note that the dynamics of the infectious class depends on the following ratio:
The pain in an osteoarthritic joint has been related to thickened synovium and to subchondral bone lesions. The inflammation of the joint lining (synovium) in osteoarthritis is characterized by involving macrophages via activation of the innate immune system (as compared to T-cell activation in the joint lining of people with rheumatoid arthritis). Pro-inflammation cytokines in osteoarthritis stimulate matrix metalloproteinases which leads to degradation and remodeling of the joint. Tissue damage or degradation of the articular cartilage or synovium leads to further release of inflammatory cytokines, driving the process.
=== Provincial funding === Shortly after the first human trials on PTX-COVID19-B began in late January, on February 11, 2021, Manitoba Premier Brian Pallister announced a "term sheet" between the province and Providence Therapeutics through which Manitoba would receive 2 million doses of PTX-COVID19-B pending its approval by Health Canada. The term sheet includes "best-price guarantee" PTX-COVID19-B. According to a provincial statement released by the Manitoba government, pending approval of the vaccine, the actual manufacturing would take place in Winnipeg by Emergent BioSolutions. Pallister said that, "Building a secure, made-in-Canada vaccine supply will put Canadians at the head of the line to get a COVID vaccine, where we belong." The down payment would be 20% with a subsequent 40% to be paid when the vaccine was approved by Health Canada; the balance would be paid on delivery of the doses. Specifics about the contract were released in April 2021: the total cost was estimated as CAD$36 million and the agreement included a clause for a non-refundable advance payment of CAD$7.2 million. Sorenson made this comment to Global News: "Under no circumstances is Manitoba going to be on the hook for $7.2 million unless they get real value out of it".
2024 – David Perlman Memorial Award, American Chemical Society, Biochemical Technology. 2024 – Founder Award, Kendall Square Association. 2024 – American Association for Cancer Research Academy, Fellow. 2023 – Australian Academy of Technological Science & Engineering, Fellow. 2021 – Outstanding Scientist Award, AAISCR Cancer Research Annual Meeting. 2019 – Honorary Degree, DSc (Medicine) University of London – Institute Cancer Research. 2017 – Catalyst Award, Science Club for Girls. 2017 – Innovation at the Intersection Award, Xconomy Awards, Biotech Week Boston. 2017 – Honorary Degree, Doctorate Utrecht University, the Netherlands. 2017 – AIMBE STEM Award, American Institute for Medical and Biological Engineering. 2015 – 20th Heinz Award for Technology, Heinz Family Foundation. 2015 – American Academy of Arts and Sciences, Fellow. 2014 – Lemelson-MIT Prize, Lemelson-MIT Program. 2014 – Pioneers of Miniaturization Prize, Lab on a Chip Lectureship at MicroTAS. 2011 – Massachusetts Academy of Sciences, Fellow. 2011 – Biomedical Engineering Society, Fellow. 2011 – Brown Engineering Alumni Medal, Brown University School of Engineering. 2011 – Thomas A. McMahon Mentoring Award, MIT, Health Sciences & Technology. 2010 – John J. and Dorothy Wilson Professor, MIT, HST & EECS, Endowed Chair. 2010 – Young Investigator Award, American College of Clinical Pharmacology. 2009 – American Society for Clinical Investigation, Fellow. 2005 – American Institute for Medical and Biological Engineering, Fellow. 2003 – Y.C. Fung Young Investigator Award, American Society of Mechanical Engineers.
Sources: en.wikipedia.org
==== Sai ==== Sai appears in Demon Days: X-Men. She is an adventurous Japanese samurai accompanied by a wolf named Logan who comes from a variation of ancient Japan where humans used to coexist with yōkai until the avarice within humans caused a conflict between both species.
Carboxylation is a chemical reaction in which a carboxylic acid is produced by treating a substrate with carbon dioxide. The opposite reaction is decarboxylation. In chemistry, the term carbonation is sometimes used synonymously with carboxylation, especially when applied to the reaction of carbanionic reagents with CO2. More generally, carbonation usually describes the production of carbonates.
The term dog has been used as a synonym for sausage since the 1800s, possibly from accusations that sausage makers used dog meat in their sausages. In Germany the consumption of dog meat was common in Saxony, Silesia, Anhalt, and Bavaria during the 19th and 20th centuries. Hot dogs occasionally contained it. An early use of the term hot dog in reference to the sausage-meat appears in 1884:
Sources: en.wikipedia.org
Cross linking antibody induced aggregation of Thy1 cause death of thymocytes and mesangial cells mainly by apoptosis despite Bcl2 upregulation. The death of mesangial cells seems to be apoptosis by TUNEL staining or annexin V staining, but electron microscopy suggest it is necrosis.
Because peptide chains have a directionality conferred by their N-terminus and C-terminus, β-strands too can be said to be directional. They are usually represented in protein topology diagrams by an arrow pointing toward the C-terminus. Adjacent β-strands can form hydrogen bonds in antiparallel, parallel, or mixed arrangements. In an antiparallel arrangement, the successive β-strands alternate directions so that the N-terminus of one strand is adjacent to the C-terminus of the next. This is the arrangement that produces the strongest inter-strand stability because it allows the inter-strand hydrogen bonds between carbonyls and amines to be planar, which is their preferred orientation. The peptide backbone dihedral angles (φ, ψ) are about (–140°, 135°) in antiparallel sheets. In this case, if two atoms Cαi and Cαj are adjacent in two hydrogen-bonded β-strands, then they form two mutual backbone hydrogen bonds to each other's flanking peptide groups; this is known as a close pair of hydrogen bonds. In a parallel arrangement, all of the N-termini of successive strands are oriented in the same direction; this orientation may be slightly less stable because it introduces nonplanarity in the inter-strand hydrogen bonding pattern. The dihedral angles (φ, ψ) are about (–120°, 115°) in parallel sheets.
Balanced anesthesia, also known as multimodal anesthesia (also spelt: anaesthesia), is a technique used to induce and maintain anesthesia in patients undergoing surgery or certain medical procedures. This method employs a combination of anesthetic agents and other drugs – and techniques – to selectively target various aspects of the central nervous system, allowing for a tailored anesthetic experience based on the individual patient's needs and the specific requirements of the procedure. The specialist physician (in Canadian and American English: anesthesiologist; in Commonwealth and British English: anaesthetist) or veterinarian evaluates various patient factors prior to selecting an anesthetic approach. These factors include major organ function, general condition, and compensatory capacity (ability to function despite stressors). In balanced anesthesia, appropriate agents are used in combination, at carefully-calibrated levels. The concept of balanced anesthesia was first introduced by John Silas Lundy in 1926 and has since become the predominant method of anesthesia in modern medical practice.
=== St–Sz === Frank Stahl (1929–2025), US molecular biologist known for the Meselson-Stahl experiment Donald F. Steiner (1930–2014). American biochemist at the University of Chicago, who made ground breaking discoveries in the treatment of diabetes. Member Natl. Acad. Sci. USA Joan Steitz FRS (foreign associate) (b. 1941). American biochemist at Yale University, best known for her work on RNA. Member Natl. Acad. Sci. USA. Thomas A. Steitz FRS (foreign associate) (1940–2018). American biochemist at Yale University, best known for his pioneering work on the ribosome. Nobel Prize in Chemistry, 2009. Member Natl. Acad. Sci. USA. Marjory Stephenson FRS (one of the first two women elected) (1885-1948). British biochemist and microbiologist at Cambridge University, most widely remembered for her seminal book, Bacterial Metabolism. Audrey Stevens (1932–2010). American biochemist at Oak Ridge National Laboratory, co-discoverer of RNA polymerase. Member Natl. Acad. Sci. USA. Bruce Stone (1928–2008). Australian biochemist known for work in cereal and grass polysaccharides. Foundation Professor of Biochemistry at La Trobe University (1972–1993). Lubert Stryer (1938–2024). American biophysicist at Stanford who pioneered the use of fluorescence spectroscopy, particularly Förster resonance energy transfer, to monitor the structure and dynamics of biological macromolecules. He is best known for his textbook Biochemistry. Member Natl. Acad. Sci. USA. Paul K.
Sources: en.wikipedia.org
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.
Reverse-phase high-performance liquid chromatography is commonly used to assess purity. Mass spectrometry is used to confirm molecular identity. These methods are typical for synthetic peptides and research chemicals.
Dihexa is not approved as a drug in major jurisdictions. It is often sold as a research chemical, which is not the same as a medicine. Its legal status can vary by country and may change.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.